Browse the evidence

Reduced gut microbial diversity (alpha-diversity) and specific taxonomic shifts (e.g., depletion of Akkermansia muciniphila and Faecalibacterium prausnitzii) are consistently associated with obesity and metabolic syndrome, serving as a marker of a less resilient microbiome.

Focus on dietary patterns that support microbial diversity (e.g., fiber-rich diets) rather than seeking simple diagnostic ratios. A diverse diet supports a resilient microbiome, which is associated with better metabolic health.

Short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate promote satiety and improve metabolic health by stimulating GLP-1 and PYY secretion and modulating gut-brain signaling, despite inconsistent fecal level measurements in obesity.

Consume fiber-rich foods to support SCFA production. This supports satiety hormones (GLP-1/PYY) and gut health, even if direct measurement of SCFAs is not feasible.

Elevated circulating branched-chain amino acids (BCAAs) and imidazole propionate (IMP) are causally linked to insulin resistance and type 2 diabetes, serving as predictive biomarkers years before clinical onset.

Monitor metabolic health through regular check-ups. Dietary patterns that improve insulin sensitivity (e.g., balanced macronutrients, fiber) can help manage BCAA and IMP levels.

Metabolic bariatric surgery (specifically malabsorptive procedures like Roux-en-Y gastric bypass) offers higher remission rates for Type 2 Diabetes than restrictive procedures (like sleeve gastrectomy), particularly in patients with severe obesity (BMI ≥ 35).

If you have severe obesity (BMI 35+) and Type 2 Diabetes, metabolic surgery (specifically bypass) is the most effective intervention for remission, offering double the success rate of sleeve gastrectomy. While invasive, it provides superior long-term glycemic control and lower relapse rates compared to other surgical options.

Incretin-based medications (GLP-1 RAs, dual/tri-agonists) achieve high rates of glycemic control (HbA1c ≤ 6.5%) and weight loss, but technically do not constitute 'remission' as defined by the consensus (which requires being off medication), as the effect persists only while taking the drug.

Newer incretin-based medications (like GLP-1 and dual/tri-agonists) are highly effective at lowering blood sugar and promoting weight loss, with some trials showing over 80% of patients reaching normal HbA1c levels. However, this control is dependent on continuing the medication and does not constitute 'remission' in the strict sense of being off all drugs.

Discontinuation of incretin agonists (GLP-1/GIP) leads to significant weight regain (approx. two-thirds of lost weight) within weeks, indicating that current pharmacological efficacy is not sustainable without continuous treatment.

Current GLP-1 and GIP medications are not a one-time fix for obesity. If you stop taking them, you will likely regain most of the weight you lost. This suggests that obesity management with these drugs is a long-term commitment, similar to other chronic conditions, and requires ongoing medical supervision and cost consideration.

Physical activity levels are significantly lower in obese patients with Type 2 Diabetes compared to non-obese patients, and this difference persists even when total energy intake is similar between groups.

Obese diabetic patients tend to be significantly less physically active than non-obese patients. Since calorie intake may not differ, increasing physical activity is a critical component of weight management.

Early weight loss (first 14 days) in a behavioral weight management program predicts long-term weight loss trajectory patterns, specifically differentiating those who achieve sustained loss from those who do not, although it does not distinguish between different types of successful sustained loss patterns.

If you are starting a weight loss program, do not judge your success or failure in the first two weeks. The data shows that how much you lose in the first 14 days does not predict *how* you will lose weight long-term (steady vs. plateau), but it does predict *if* you will lose weight significantly. If you are not losing weight early, do not quit. Instead, focus on adherence. If you are losing weight, do not expect that fast loss will continue linearly. The key to long-term success is staying in the program for the long haul, regardless of the initial speed.

Once-daily oral semaglutide (up to 14 mg) reduces systolic blood pressure and total cholesterol in patients with type 2 diabetes.

If you have Type 2 Diabetes, adding oral semaglutide to your current regimen can help lower your systolic blood pressure and total cholesterol. The standard protocol starts at a low dose (3 mg) and increases to 14 mg daily over two months to minimize side effects. This oral option offers cardiovascular protection similar to the injectable version, which may be easier for you to stick with long-term.

Oral semaglutide consistently reduces LDL cholesterol and triglycerides, but its effect on HDL cholesterol is inconsistent and clinically insignificant.

Oral semaglutide helps lower 'bad' cholesterol (LDL) and triglycerides in most patients with Type 2 Diabetes. However, do not expect it to reliably raise 'good' cholesterol (HDL), as studies show mixed and clinically insignificant results for HDL changes.

Orlistat causes mechanism-specific gastrointestinal adverse effects (steatorrhea, fecal urgency, flatulence) due to fat malabsorption, but these are generally manageable with dietary modification.

If you take Orlistat, you may experience oily stools, gas, or urgency, especially if you eat high-fat meals. To minimize these effects, limit your fat intake and take vitamin supplements as recommended. These side effects are predictable and manageable, but they require dietary awareness.

Continuous Positive Airway Pressure (CPAP) therapy effectively improves daytime sleepiness and quality of life in Obstructive Sleep Apnoea (OSA) patients, but its impact on cardiometabolic outcomes is uncertain and secondary prevention trials have failed to demonstrate significant modification of cardiovascular events.

CPAP is the most effective treatment for stopping snoring and fixing daytime sleepiness in OSA patients. However, do not expect it to automatically fix your heart health or blood sugar levels, as evidence for those benefits is weak. If you struggle with the mask, talk to your doctor about alternatives like oral appliances or nerve stimulation, as adherence is a major hurdle.

GIP receptor (GIPR) antagonism enhances the weight-loss efficacy of GLP-1 receptor agonists by removing an inhibitory tone on central nervous system (CNS) satiety circuits, specifically within hindbrain GABAergic neurons.

If you are using a GLP-1 medication (like semaglutide or liraglutide) and experiencing significant side effects like nausea without sufficient weight loss, newer therapies that block the GIP receptor (antagonism) while activating GLP-1 may be more effective and tolerable. This works by removing a natural 'brake' on your brain's satiety signals, allowing the medication to work more efficiently.

Sedentary behavior exceeding 9 hours per day significantly increases the odds of hypertension and diabetes, with stronger associations observed in socioeconomically vulnerable populations (Basic Livelihood Security recipients) compared to non-recipients.

If you sit for more than 9 hours a day, your risk for high blood pressure and diabetes increases significantly, especially if you have limited income. To mitigate this, do not sit continuously for long periods. Break up your sitting time with light activity, such as standing or walking for a few minutes, as this improves blood sugar control and vascular health even if you do not have time for formal exercise.

Below-average intake of energy and carbohydrates is associated with increased odds of hypertension and diabetes in socioeconomically vulnerable populations, contradicting the assumption that low-calorie diets are universally protective.

For older adults with limited income, eating very little or avoiding carbohydrates may actually increase your risk of high blood pressure and diabetes. Ensure you are consuming adequate energy and carbohydrates from nutritious sources to support metabolic health, as deficiency in this group is linked to higher disease odds.

Using gender-specific portion sizes (GS-PS) in food frequency questionnaires improves the accuracy of absolute nutrient intake estimates compared to using common portion sizes, but does not improve the accuracy of nutrient density estimates.

If you are tracking your absolute nutrient intake (e.g., total grams of protein or calories) using a food diary or app, using gender-specific portion estimates can improve accuracy. However, if you are tracking nutrient density (e.g., percentage of calories from fat or protein), using standard portion sizes is likely sufficient as gender-specific adjustments do not significantly change these ratios.

Increasing dietary cholesterol intake to levels substantially above the previous 300 mg/day limit does not negatively impact LDL-C, HDL-C, or triglyceride levels when consumed within the context of a healthy, low-carbohydrate weight loss diet.

If you are following a healthy low-carbohydrate diet and losing weight, you do not need to restrict your cholesterol intake to 300 mg per day. Increasing your intake of cholesterol-rich foods like eggs, while reducing refined grains and sugars, does not appear to negatively affect your blood lipid levels (LDL, HDL, triglycerides). Focus on the overall quality of your diet rather than a specific cholesterol number.

Comprehensive obesity care requires the integration of behavioral health support to address weight stigma, disordered eating, and the psychosocial impacts of large magnitude weight loss, which medical management alone cannot resolve.

Obesity treatment involves more than just weight loss; it includes managing the psychological impact of the disease. Seek out behavioral health support to address weight stigma, disordered eating, and the emotional changes that come with significant weight loss.

Incretin-based therapies (GLP-1 and GLP-1/GIP RAs) induce substantial weight loss that is predominantly derived from fat mass, resulting in the relative preservation or improvement of lean body mass percentage and muscle quality, despite absolute reductions in lean mass.

If you are using GLP-1 or GLP-1/GIP medications for weight loss, expect to lose mostly fat. You will likely lose some muscle mass in absolute terms, but your body composition will improve because you are losing fat faster than muscle. To maximize this benefit, prioritize protein intake (1.2-1.6 g/kg/day) and engage in resistance training to signal your body to keep muscle tissue.

Physical activity and exercise provide significant health benefits for adults with overweight or obesity independent of weight loss, including improvements in body composition quality, cardiorespiratory fitness, and metabolic health.

Prioritize regular physical activity regardless of your current weight. Focus on building cardiorespiratory fitness and muscle strength, as these provide health benefits even if you do not lose weight. Do not let the absence of scale movement discourage you from exercising.

GLP-1 receptor agonists (semaglutide and tirzepatide) produce highly heterogeneous weight loss outcomes, with 'super responders' achieving >15% body weight loss while 'minimal responders' achieve <5%, driven by distinct pre-treatment clinical phenotypes rather than uniform biological response.

If you are taking a GLP-1 medication like Ozempic or Mounjaro, understand that your weight loss outcome is not guaranteed to be 'super' (>15% loss). Your pre-existing health conditions (like sleep apnea, psoriasis, or fibromyalgia) may predict how well you respond. Focus on the health benefits of even moderate weight loss (5-15%) rather than comparing yourself to 'super responder' statistics, as individual biology plays a massive role in the final result.

Pre-treatment clinical phenotypes, specifically the presence or absence of certain comorbidities, are strongly associated with the likelihood of being a 'super responder' to specific GLP-1RA brands.

Your existing health conditions might predict how well a specific weight-loss drug will work for you. For example, those without fibromyalgia or osteoarthritis might respond better to Zepbound, while those with psoriasis might respond better to Wegovy. Discuss your full medical history with your provider to help select the most appropriate GLP-1RA.

Tirzepatide (Zepbound/Mounjaro) is associated with a higher proportion of 'super responders' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy) in real-world settings.

If you are choosing between GLP-1 medications, tirzepatide (Zepbound/Mounjaro) may offer a higher probability of 'super response' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy). However, individual response varies, and your specific health profile should guide the choice.

GLP-1 receptor agonists and incretin co-agonists reduce total body weight primarily through adipose tissue loss, but this process involves an absolute reduction in lean mass (skeletal muscle) that typically accounts for 20–30% of the total weight lost.

If you are taking GLP-1 medications, expect to lose some muscle along with fat. To minimize this, prioritize resistance training and adequate protein intake. This helps preserve strength and metabolic health despite the inevitable lean mass reduction.